The lupus nephritis management renaissance
- 1 February 2022
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 101 (2), 242-255
- https://doi.org/10.1016/j.kint.2021.09.012
Abstract
No abstract availableFunding Information
- National Institutes of Health (R01-AR-071947, UH2 AR067688)
This publication has 122 references indexed in Scilit:
- Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroidsAnnals Of The Rheumatic Diseases, 2013
- Urinary Vascular Cell Adhesion Molecule, But Not Neutrophil Gelatinase-associated Lipocalin, Is Associated with Lupus NephritisThe Journal of Rheumatology, 2012
- ForewordKidney International Supplements, 2012
- Strategy for second kidney biopsy in patients with lupus nephritisNephrology Dialysis Transplantation, 2011
- Fractalkine/CX3CL1: A Potential New Target for Inflammatory DiseasesMolecular Interventions, 2010
- The complex nature of serum C3 and C4 as biomarkers of lupus renal flareLupus, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal studyArthritis Research & Therapy, 2009
- Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritisKidney International, 1996